These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30184183)

  • 1. Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine in Papua New Guinean Infants.
    Pomat WS; van den Biggelaar AHJ; Wana S; Francis JP; Solomon V; Greenhill AR; Ford R; Orami T; Passey M; Jacoby P; Kirkham LA; Lehmann D; Richmond PC;
    Clin Infect Dis; 2019 Apr; 68(9):1472-1481. PubMed ID: 30184183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
    Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
    PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial.
    Orami T; Aho C; Ford RL; Pomat WS; Greenhill A; Kirkham LA; Masiria G; Nivio B; Britton KJ; Jacoby P; Richmond PC; van den Biggelaar AHJ; Lehmann D
    Vaccine; 2023 Aug; 41(37):5392-5399. PubMed ID: 37479616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Pneumococcal and
    Martinovich KM; Rahman T; de Gier C; Seppanen EJ; Orami T; Granland CM; Francis J; Yoannes M; Corscadden KJ; Ford R; Jacoby P; van den Biggelaar AHJ; Bakaletz LO; Cripps AW; Lehmann D; Richmond PC; Pomat WS; Kirkham LS; Thornton RB
    Front Immunol; 2021; 12():725244. PubMed ID: 34447389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life.
    Rahman T; de Gier C; Orami T; Seppanen EJ; Granland CM; Francis JP; Michael A; Yoannes M; Corscadden KJ; Ford RL; Martinovich KM; Jacoby P; van den Biggelaar AHJ; Lehmann D; Richmond PC; Pomat WS; Thornton RB; Kirkham LS
    Vaccine; 2021 Jun; 39(26):3486-3492. PubMed ID: 34024658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
    Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
    Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
    Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
    Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
    Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
    Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
    Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
    PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Platt HL; Greenberg D; Tapiero B; Clifford RA; Klein NP; Hurley DC; Shekar T; Li J; Hurtado K; Su SC; Nolan KM; Acosta CJ; McFetridge RD; Bickham K; Musey LK;
    Pediatr Infect Dis J; 2020 Aug; 39(8):763-770. PubMed ID: 32639460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
    de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
    Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.
    van Westen E; Wijmenga-Monsuur AJ; van Dijken HH; van Gaans-van den Brink JA; Kuipers B; Knol MJ; Berbers GA; Sanders EA; Rots NY; van Els CA
    Clin Infect Dis; 2015 Aug; 61(3):342-9. PubMed ID: 25838290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Senders S; Klein NP; Tamimi N; Thompson A; Baugher G; Trammel J; Peng Y; Giardina P; Scully IL; Pride M; Center KJ; Gruber WC; Scott DA; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):596-603. PubMed ID: 38535409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique.
    Massora S; Lessa FC; Moiane B; Pimenta FC; Mucavele H; Chaúque A; Cossa A; Verani JR; Tembe N; da Gloria Carvalho M; Muñoz-Almagro C; Sigaúque B
    Vaccine; 2019 Dec; 37(51):7470-7477. PubMed ID: 31575493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.
    Korbal P; Wysocki J; Jackowska T; Kline M; Tamimi N; Drozd J; Lei L; Peng Y; Giardina PC; Gruber W; Scott D; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):587-595. PubMed ID: 38456705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.